Get In Touch with Cayuga Biotech
Please tell us a little bit about yourself and why you'd like to get connected. Cayuga Biotech + SOSV will follow up with you via email.
Cayuga Biotech is a clinical-stage company developing novel therapeutics to address hemorrhage by harnessing the body’s innate ability to stop bleeding. Cayuga’s pipeline includes CAY001 (polyP-SNP complex) in development for life-threatening major hemorrhage; CAY002, a discovery-stage program for inherited bleeding disorders, and; a portfolio of additional early-stage programs across the healing continuum.
Across all sources of bleeding, the probability of death increases 1 % for every 3 minutes of uncontrolled hemorrhage.
Bleeding causes a lot of negative outcomes for patients, so stopping the bleeding has many benefits. Not only are you saving their lives by reducing blood loss, but you can actually reduce the time it takes for them to heal as well.
Please tell us a little bit about yourself and why you'd like to get connected. Cayuga Biotech + SOSV will follow up with you via email.
No Offer, Solicitation, Advice, or Recommendation
Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.